Overview

Survodutide is an investigational dual agonist peptide that targets both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. It is being researched as a powerful tool in obesity, metabolic syndrome, insulin resistance, and non-alcoholic steatohepatitis (NASH). Survodutide mimics natural incretin hormones, helping to regulate appetite, glucose metabolism, insulin sensitivity, and fat distribution. It is known to promote weight loss, visceral fat reduction, and potential liver health improvement.

Key Benefits / Research Highlights

• Potent weight loss support through dual GLP-1 and GIP receptor activation
• Suppresses appetite and enhances satiety
• Improves glucose metabolism and insulin sensitivity
• Supports fatty liver and liver inflammation (NASH)
• Reduces visceral (belly) fat preferentially over lean muscle
• May support cardiovascular and metabolic health markers

Link to studies

https://pubmed.ncbi.nlm.nih.gov/?term=Survodutide